Insulet Corporation $PODD Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its holdings in Insulet Corporation (NASDAQ:PODD) by 52.8% during the first quarter, Holdings Channel reports. The firm owned 39,134 shares of the medical instruments supplier’s stock after selling 43,809 shares during the period. First Trust Advisors LP’s holdings in Insulet were worth $8,212,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PODD. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Insulet in the fourth quarter valued at $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the fourth quarter valued at $28,000. DV Equities LLC acquired a new stake in shares of Insulet during the 4th quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet during the 4th quarter valued at $29,000.

Insulet Price Performance

PODD opened at $165.35 on Friday. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 1.15 and a beta of 1.11. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a fifty day moving average price of $155.26 and a 200 day moving average price of $198.24.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the company posted $1.02 earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts forecast that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent analyst reports. Robert W. Baird cut their target price on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Piper Sandler reduced their target price on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Bank of America decreased their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research report on Monday, May 18th. UBS Group cut Insulet from a “buy” rating to a “neutral” rating and set a $174.00 price target on the stock. in a research note on Tuesday. Finally, TD Cowen cut their price objective on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a report on Monday, June 1st. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $233.38.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: UBS Group began research coverage of Insulet, potentially increasing institutional visibility and investor attention. However, the available report does not disclose UBS’s rating or price target. Insulet research coverage started at UBS Group
• Neutral Sentiment: The legal notices concern alleged violations of federal securities laws by Insulet and certain executives. The allegations have not been proven, and the financial impact of the litigation remains uncertain. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: Several firms, including Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Bleichmar Fonti & Auld, Schall Brown & Schwartz, DJS Law Group, Rosen Law Firm, and Glancy Prongay, publicized the pending class action. The notices generally cover investors who purchased Insulet securities between February 21 or May 21, 2025, and May 26, 2026, and allege investor losses related to disclosures involving defective Omnipod manufacturing controls. Bleichmar Fonti & Auld securities lawsuit notice
• Negative Sentiment: The concentration of similar legal announcements may amplify concerns about potential damages, management accountability, regulatory scrutiny, and reputational risk, even though no judgment or settlement has been reported. Insulet investor alert from Schall Brown & Schwartz

Insider Activity

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.